COVID-19 and Cancer: Discovery of Difference in Clinical Immune Indexes

J Immunol Res. 2021 Oct 18:2021:8669098. doi: 10.1155/2021/8669098. eCollection 2021.

Abstract

Objective: This study explored the consistency and differences in the immune cells and cytokines between patients with COVID-19 or cancer. We further analyzed the correlations between the acute inflammation and cancer-related immune disorder.

Methods: This retrospective study involved 167 COVID-19 patients and 218 cancer patients. COVID-19 and cancer were each further divided into two subgroups. Quantitative and qualitative variables were measured by one-way ANOVA and chi-square test, respectively. Herein, we carried out a correlation analysis between immune cells and cytokines and used receiver operating characteristic (ROC) curves to discover the optimal diagnostic index.

Results: COVID-19 and cancers were associated with lymphopenia and high levels of monocytes, neutrophils, IL-6, and IL-10. IL-2 was the optimal indicator to differentiate the two diseases. Compared with respiratory cancer patients, COVID-19 patients had lower levels of IL-2 and higher levels of CD3+CD4+ T cells and CD19+ B cells. In the subgroup analysis, IL-6 was the optimal differential diagnostic parameter that had the ability to identify if COVID-19 patients would be severely affected, and severe COVID-19 patients had lower levels of lymphocyte subsets (CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+T cells, and CD19+ B cells) and CD16+CD56+ NK cells and higher level of neutrophils. There were significant differences in the levels of CD3+CD4+ T cells and CD19+ B cells between T1-2 and T3-4 stages as well as IL-2 and CD19+ B cells between N0-1 and N2-3 stages while no significant differences between the metastatic and nonmetastatic cancer patients. Additionally, there were higher correlations between IL-2 and IL-4, TNF-α and IL-2, TNF-α and IL-4, TNF-α and IFN-γ, and CD16+CD56+NK cells and various subsets of T cells in COVID-19 patients. There was a higher correlation between CD3+CD4+ T cells and CD19+ B cells in cancer patients.

Conclusion: Inflammation associated with COVID-19 or cancer had effects on patients' outcomes. Accompanied by changes in immune cells and cytokines, there were consistencies, differences, and satisfactory correlations between patients with COVID-19 and those with cancers.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes / immunology
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / immunology
  • COVID-19 / diagnosis
  • COVID-19 / immunology*
  • COVID-19 / pathology
  • Cytokines / blood*
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / pathology
  • Killer Cells, Natural / immunology
  • Lymphocyte Subsets / immunology
  • Lymphopenia / blood*
  • Male
  • Middle Aged
  • Monocytes / immunology*
  • Neoplasms / diagnosis
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neutrophils / immunology*
  • Retrospective Studies
  • SARS-CoV-2 / immunology
  • Young Adult

Substances

  • Cytokines